These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39092928)

  • 1. Identifying optimal dosing strategies for meropenem in the paediatric intensive care unit through modelling and simulation.
    Morales Junior R; Mizuno T; Paice KM; Pavia KE; Hambrick HR; Tang P; Jones R; Gibson A; Stoneman E; Curry C; Kaplan J; Tang Girdwood S
    J Antimicrob Chemother; 2024 Oct; 79(10):2668-2677. PubMed ID: 39092928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation.
    O'Jeanson A; Larcher R; Le Souder C; Djebli N; Khier S
    Eur J Drug Metab Pharmacokinet; 2021 Sep; 46(5):695-705. PubMed ID: 34403127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal Dosing of Meropenem in a Small Cohort of Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Tan WW; Watt KM; Boakye-Agyeman F; Cohen-Wolkowiez M; Mok YH; Yung CF; Chan YH
    J Clin Pharmacol; 2021 Jun; 61(6):744-754. PubMed ID: 33314163
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of a dosing algorithm for meropenem in critically ill patients based on a population pharmacokinetic/pharmacodynamic analysis.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Huisinga W; Zander J; Kloft C
    Int J Antimicrob Agents; 2019 Sep; 54(3):309-317. PubMed ID: 31229669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Meropenem dosing recommendations for critically ill patients receiving continuous renal replacement therapy.
    Chaijamorn W; Rungkitwattanakul D; Pattharachayakul S; Singhan W; Charoensareerat T; Srisawat N
    J Crit Care; 2020 Dec; 60():285-289. PubMed ID: 32949895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimized meropenem dosage regimens using a pharmacokinetic/pharmacodynamic population approach in patients undergoing continuous venovenous haemodiafiltration with high-adsorbent membrane.
    Padullés Zamora A; Juvany Roig R; Leiva Badosa E; Sabater Riera J; Pérez Fernández XL; Cárdenas Campos P; Rigo Bonin R; Alía Ramos P; Tubau Quintano F; Sospedra Martinez E; Colom Codina H
    J Antimicrob Chemother; 2019 Oct; 74(10):2979-2983. PubMed ID: 31335959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimising meropenem dosing in critically ill Australian Indigenous patients with severe sepsis.
    Tsai D; Stewart P; Goud R; Gourley S; Hewagama S; Krishnaswamy S; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2016 Nov; 48(5):542-546. PubMed ID: 27771187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection.
    Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C
    J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of Empirical Dosing Regimens for Meropenem in Intensive Care Unit Patients Using Population Pharmacokinetic Modeling and Target Attainment Analysis.
    An G; Creech CB; Wu N; Nation RL; Gu K; Nalbant D; Jimenez-Truque N; Fissell W; Rolsma S; Patel PC; Watanabe A; Fishbane N; Kirkpatrick CMJ; Landersdorfer CB; Winokur P
    Antimicrob Agents Chemother; 2023 Jan; 67(1):e0131222. PubMed ID: 36622154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of renal clearance and continuous renal replacement therapy on appropriateness of recommended meropenem dosing regimens in critically ill patients with susceptible life-threatening infections.
    Burger R; Guidi M; Calpini V; Lamoth F; Decosterd L; Robatel C; Buclin T; Csajka C; Marchetti O
    J Antimicrob Chemother; 2018 Dec; 73(12):3413-3422. PubMed ID: 30304491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Meropenem Population Pharmacokinetics and Dosing Regimen Optimization in Critically Ill Children Receiving Continuous Renal Replacement Therapy.
    Thy M; Urien S; Bouazza N; Foissac F; Gana I; Bille E; Béranger A; Toubiana J; Berthaud R; Lesage F; Renolleau S; Tréluyer JM; Benaboud S; Oualha M
    Clin Pharmacokinet; 2022 Nov; 61(11):1609-1621. PubMed ID: 36251162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of a non-parametric modelling for meropenem in critically ill patients using Monte Carlo simulation.
    Idoate Grijalba AI; Aldaz Pastor A; Marquet P; Woillard JB
    Eur J Clin Pharmacol; 2019 Oct; 75(10):1405-1414. PubMed ID: 31338539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma and Cerebrospinal Fluid Population Pharmacokinetics of Meropenem in Neurocritical Care Patients: a Prospective Two-Center Study.
    Kumta N; Heffernan AJ; Cotta MO; Wallis SC; Livermore A; Starr T; Wong WT; Joynt GM; Lipman J; Roberts JA
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0014222. PubMed ID: 35862757
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Covariate determinants of effective dosing regimens for time-dependent beta-lactam antibiotics for critically ill patients.
    Kaska M; Havel E; Selke-Krulichova I; Safranek P; Bezouska J; Martinkova J
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2018 Sep; 162(3):219-226. PubMed ID: 29582860
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics/Pharmacodynamics and Clinical Outcomes of Meropenem in Critically Ill Patients.
    Boonpeng A; Jaruratanasirikul S; Jullangkoon M; Samaeng M; Wattanavijitkul T; Bhurayanontachai R; Pattharachayakul S
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0084522. PubMed ID: 36226944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of standard-dose meropenem in critically ill patients on continuous renal replacement therapy: a prospective observational trial.
    Onichimowski D; Będźkowska A; Ziółkowski H; Jaroszewski J; Borys M; Czuczwar M; Wiczling P
    Pharmacol Rep; 2020 Jun; 72(3):719-729. PubMed ID: 32301057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.
    Ehmann L; Zoller M; Minichmayr IK; Scharf C; Maier B; Schmitt MV; Hartung N; Huisinga W; Vogeser M; Frey L; Zander J; Kloft C
    Crit Care; 2017 Oct; 21(1):263. PubMed ID: 29058601
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Plasma and Interstitial Tissue Fluid Pharmacokinetics of Meropenem Demonstrate the Need for Increasing Dose and Infusion Duration in Obese and Non-obese Patients.
    Busse D; Simon P; Schmitt L; Petroff D; Dorn C; Dietrich A; Zeitlinger M; Huisinga W; Michelet R; Wrigge H; Kloft C
    Clin Pharmacokinet; 2022 May; 61(5):655-672. PubMed ID: 34894344
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing Meropenem in Highly Resistant Klebsiella pneumoniae Environments: Population Pharmacokinetics and Dosing Simulations in Critically Ill Patients.
    Truong AQ; Dao XC; Vu DH; Nguyen HA; Do THG; Tran NT; Tran NM; Vu NB; Pham HN; Bui VC; Trinh TA; Dang QT; Nguyen GB; Lipman J; Cotta MO; Roberts JA
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0032122. PubMed ID: 36197095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetics of meropenem in critically ill children with different renal functions.
    Rapp M; Urien S; Foissac F; Béranger A; Bouazza N; Benaboud S; Bille E; Zheng Y; Gana I; Moulin F; Lesage F; Renolleau S; Tréluyer JM; Hirt D; Oualha M
    Eur J Clin Pharmacol; 2020 Jan; 76(1):61-71. PubMed ID: 31654149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.